Status:

ACTIVE_NOT_RECRUITING

Investigation of Immune Amnesia Following Measles Infection in Select African Regions

Lead Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborating Sponsors:

Johns Hopkins University

Conditions:

Measles Infection

Eligibility:

All Genders

1-15 years

Brief Summary

The goal of this observational study is to investigate the effects of measles virus (MeV) infection on pre-existing immunity, vaccine response, and susceptibility to subsequent illness in children age...

Detailed Description

This is a prospective, observational, longitudinal study to be conducted in West Africa. Eligible children will be enrolled into 1 of 2 arms: acute MeV infection (cases) or no acute MeV infection (con...

Eligibility Criteria

Inclusion

  • Aged 1 to 15 years.
  • Ability of the participant's legal or culturally acceptable representative to provide informed consent.
  • Ability to give assent, as appropriate.
  • Stated willingness of parent/guardian and participant as appropriate, to comply with all study procedures.
  • Willingness to receive rabies vaccine.
  • Meet the criteria for assignment to Group 1 or Group 2, as follows:
  • Group 1, cases (acute MeV infection):
  • Clinical signs and symptoms suggestive of acute MeV infection (Koplik spots or skin rash) AND
  • Laboratory confirmed measles:
  • Upper respiratory specimen (swab) PCR for measles positive, OR
  • Serum IgM for measles positive.
  • Group 2, controls (no acute MeV infection):
  • No clinical signs and symptoms suggestive of acute MeV infection (Koplik spots or skin rash) AND
  • Upper respiratory specimen (swab) PCR negative for MeV AND
  • Serum measles IgM negative AND
  • Serum measles IgG positive and previously vaccinated for measles (2nd dose will be offered if appropriate). If serum measles IgG is negative, participant must be willing to be vaccinated regardless of prior measles vaccine history to meet this criterion.

Exclusion

  • HIV infection or any other immunosuppressive condition or medications.
  • Pregnant or lactating.
  • History of prior measles or immunologic evidence of prior measles in the absence of prior measles vaccination.
  • Severe anemia, defined as hemoglobin less than 8 g/dL.
  • Any acute or chronic condition which, in the opinion of the investigator, constitutes a contraindication to participation in this study.

Key Trial Info

Start Date :

January 16 2024

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

June 1 2026

Estimated Enrollment :

256 Patients enrolled

Trial Details

Trial ID

NCT06153979

Start Date

January 16 2024

End Date

June 1 2026

Last Update

May 29 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Partnership of Clinical Research in Guinea, Partenariat Pour La Recherche Clinique en Guinée (PREGUI)

Conakry, Guinea

2

University Clinical Research Center (UCRC) University of Sciences, Techniques and Technologies of Bamako

Bamako, Mali